跳至主要内容
临床试验/DRKS00019854
DRKS00019854已完成不适用

Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) - MEASURE-AD

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 1,593 人开始时间: 2020年1月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,593

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
12 Years 至 one(—)
性别
All

入选标准

  • physician confirmed diagnosis of atopic dermatitis
  • moderate to severe AD patients who are (i) current candidates for systemic therapy for AD according to the HCP, or (ii) currently receiving systemic therapy for AD.
  • medication history available within the last 6 months
  • able to understand the questionnaires, with parental support as required for adolescents
  • willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable

排除标准

  • Patients will be excluded if currently participating in interventional clinical trial(s). Participation in another non-interventional study or registry does not exclude a patient from this study.

研究者

相似试验